Exciting times ahead at OBH as we win grant funding from InnovateUK for a ‘Real World Outcomes’ feasability study. We will be testing the feasibility of a product to generate Real World Evidence for Life Science companies in pharmaceuticals and devices to test the ability to use existing healthcare and administrative data to measure the impact of an intervention, device, technology or drug, on health outcomes.
Why is it needed?
- Innovations and tech interventions want to measure the impact their service/product has on people’s outcomes
- Pharmaceuticals increasingly needing to show Real World evidence (RWE) of impact, post licensing surveillance, and as a condition of regulatory/licensing approval
- Move from payment for each pill to payment for outcomes
- NHS providers asked to improve outcomes under new outcomes-based contracts are looking at which interventions can have the most impact
We are very excited for this opportunity because by driving the system value of pharmaceuticals and devices, we can create system efficiencies and hopefully ease demands of services.
